Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma

被引：0
|
作者：
Ito, M. [1 ,2 ]
Miyata, Y. [2 ]
Hirano, S. [2 ]
Morihara, N. [2 ]
Irisuna, F. [2 ]
Takemoto, M. [2 ]
Tsutani, Y. [1 ]
Okada, M. [2 ]
机构：
[1] Kindai Univ, Osaka, Japan
[2] Hiroshima Univ, Hiroshima, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
KRAS; mTOR; squamous cell carcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP02.01-09
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [1] Targeting KRAS G12C mutation in lung adenocarcinoma
    Rohatgi, Anjali
    Govindan, Ramaswamy
    LUNG CANCER, 2022, 165 : 28 - 33
  • [2] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [3] The MET Inhibitor Tepotinib Potentially Inhibits KRAS G12C and SHOC2 in KRAS G12C Non-Small Cell Lung Cancer (NSCLC)
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. Prasad
    Prasad, A.
    Jantus-Lewintre, E.
    Ito, M.
    Cardona, A. F.
    Arrieta, O.
    Cao, P.
    Cai, X.
    Xing, B.
    Pedraz-Valdunciel, C.
    Dantes, Z.
    Sullivan, I.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez-Cao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S112 - S112
  • [4] Antitumor Effect of the KRAS G12C Inhibitor Sotorasib combined with Radiotherapy and Carboplatin/Cisplatin in human Lung Carcinoma Cell Lines
    Maltzahn, Christin
    Patties, Ina
    Kortmann, Rolf-Dieter
    Seidel, Clemens
    Glasow, Annegret
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S101 - S101
  • [5] ONCOGENIC KRAS G12C MUTATION DERIVED INHIBITOR DEVELOPMENT
    Leveles, Ibolya
    Koppany, Gergely
    Nyiri, Kinga
    Vertessy, G. Beata
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2019, 75 : E117 - E117
  • [6] Selinexor (XPO1 inhibitor) in combination with tepotinib (MET inhibitor) potentially inhibits SHOC2 and KRAS G12C in KRAS G12C mutant non-small cell lung cancer
    Rosell, R.
    Jain, A.
    Codony-Servat, J.
    Shivamallu, C.
    Kollur, S. P.
    Prasad, A.
    Vishwanath, P.
    Jantus Lewintre, E.
    Ito, M.
    Cardona Zorrilla, A. F.
    Arrieta Rodriguez, O. G.
    Pedraz-Valdunciel, C.
    Gonzalez Nieto, J.
    Aguilar, A.
    Molina-Vila, M. A.
    Gonzalez Cao, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1188 - S1188
  • [7] KRAS G12C inhibitor combination therapies: current evidence and challenge
    Miyashita, Hirotaka
    Kato, Shumei
    Hong, David S.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [8] Process Research for ZG1077, a KRAS G12C Inhibitor
    Feng, Wei-Dong
    Lv, Bin-Hua
    Ye, Wei
    Wang, Cai
    Jin, Lin-Yong
    Wang, Run-Qing
    Lian, Chang-Min
    You, Kuan-Hong
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (10) : 2986 - 2996
  • [9] RESISTANT KRAS(G12C) INHIBITOR SUBCLONES EXHIBIT HETEROGENEOUS ALTERATIONS
    不详
    CANCER DISCOVERY, 2022, 12 (01) : 13 - 13
  • [10] Application of Compositions Comprising a KRAS G12C Inhibitor and an EGFR Inhibitor for the Potential Treatment of Cancer
    Kargbo, Robert B.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (09): : 1400 - 1401
12345